Published in Neurology on February 17, 2016
Environmental control of autoimmune inflammation in the central nervous system. Curr Opin Immunol (2016) 0.81
Obesity and Multiple Sclerosis Susceptibility: A Review. J Neurol Neuromedicine (2016) 0.75
Multiple Sclerosis in Latin Americans: Genetic Aspects. Curr Neurol Neurosci Rep (2017) 0.75
Botulinum Toxin Treatment in Multiple Sclerosis-a Review. Curr Treat Options Neurol (2017) 0.75
Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives. Mult Scler Int (2017) 0.75
The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years. Trends Genet (2017) 0.75
Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol (1992) 3.53
Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology (1991) 3.05
Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology (1979) 2.07
All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm (2010) 2.02
Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology (1999) 1.90
Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology (2002) 1.82
The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology (2010) 1.63
Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry (2013) 1.56
Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology (2003) 1.56
The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis (2009) 1.36
Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm (2009) 1.33
Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care (2011) 1.26
The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ (2013) 1.23
Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol (2011) 1.15
Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord (2013) 0.98
Late-onset multiple sclerosis. J Am Geriatr Soc (2001) 0.97
The incidence and prevalence of reported multiple sclerosis. Ann Neurol (1981) 0.90
Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci (2004) 0.89
Late onset multiple sclerosis. Neurologia (2010) 0.84
The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs (2004) 0.83